Starting the evaluation for transplant
My son is 22 years old and is getting sick every time he comes off IV meds the dr.s are telling us to get prepared to start the evaluation process. Iam watching my son get sicker and thinner aLl the time And as soon as he comes off the ivs his gets sick again to watch him get disappointed is hard to handle. So I am trying to prepare my self as what this process is going to be like. Can any one tell me about the process and the Drs. have told us in the past that success rate isn't very good but when look on here I read many success stories. I don't know what to think any info would be very helpful
ConclusionsTherapeutic drug monitoring-guided meropenem may be a sound new therapeutic option in eradicating multidrug resistant Acinetobacter and offer a novel therapeutic option in the field of personalized medicine.
Authors: Ruszel N, Kubisa B, Lisowski P, Piotrowska M, Kubisa MJ, Brykczyński M, Wojtyś M, Pieróg J, Czarnecka M, Wójcik J, Wójcik N, Sielicki P, Bielewicz M, Grodzki T PMID: 31708987 [PubMed]
Conclusion. Further investigation to confirm the hypothesis that C9-PQS may be associated with increased antibiotic usage for pulmonary exacerbations is warranted as AQ-dependent signalling is a potential future target for anti-virulence therapies. PMID: 31671047 [PubMed - as supplied by publisher]
The severe form of CF liver disease, multilobular biliary cirrhosis (MBC) is associated with the almost invariable development of portal hypertension (PH) and the complications of variceal bleeding [1 –4] and unusually hepatic encephalopathy  or liver failure requiring transplantation . These features in combination with splenomegaly and laboratory evidence of hypersplenism facilitate a diagnosis of MBC/PH which can be confirmed with non-invasive ultrasonography [2,7–9] and magnetic res onance imaging.
Cystic fibrosis (CF) is the most common genetically inherited disease in the Caucasian population . Respiratory manifestations of CF include reduction of mucus clearance, chronic pulmonary infections, and bronchiectasis, causing a progressive respiratory failure that is the primary cause of death in CF patients. Advanced CF might be complicated by pulmonary hypertension, right ventricular hypertrophy, and right heart failure . Bilateral lung transplantation (LUTX) is a viable option for CF, providing a significant survival benefit .
Pseudomonas aeruginosa (P. aeruginosa) is a common pathogen in the setting of lung transplantation.1 Most recipients become chronically colonized with P. aeruginosa. Previously we have demonstrated in a subgroup of patients with non-cystic fibrosis (CF) bronchiectasis who are chronically colonized with P. aeruginosa, the presence of high titres of IgG2 antibodies specific for the O-antigen of lipopolysaccharide (LPS) which impair serum-mediated killing of the cognate strain.2 In contrast to the serum bactericidal effect normally associated with antibody, this ‘inhibitory antibody’ prevented immune killing of the infecting strain.
In individuals with cystic fibrosis (CF), severe pulmonary or liver disease is frequently addressed with lung or liver transplant, respectively. Specific endocrine co-morbidities including diabetes mellitus, osteoporosis, and adrenal insufficiency accompany solid organ transplant and may be particularly problematic in individuals with CF, who are already at increased risk of diabetes and compromised bone health. Diabetes and osteoporosis screening and initiation of appropriate preventive measures are recommended prior to transplant.
Researchers are developing a smart shirt that -together with a mobile app â can reliably measure breathing in healthy people while carrying out a range of everyday activities. This means they can now test out the smart shirts with patients who have chronic obstructive pulmonary disease (COPD). If successful, they hope this will allow doctors to monitor patients remotely for early signs that their condition is getting worse. The research was presented by Denise MannÃ©e, a technical physician and PhD candidate at Radboud University Medical Centre in The Netherlands. In a release she said: "...
In this study, the contractile and proliferative properties of ASM cells isolated from healthy donor and CF transplant lungs were compared. Proliferation assays showed CF ASM proliferate at a higher rate than healthy cells. Through calcium analysis, no differences in contractile activation was found, however, CF ASM lagged in their reuptake of calcium. The combination CFTR corrector and potentiator, VX-809/770, was used to restore proper CFTR function in CF ASM which resulted in a reduction in proliferation and in a normalization of calcium reuptake kinetics. These results show that improper CFTR function in ASM cause intr...
Despite improvements in the control of respiratory infections and life expectancy in cystic fibrosis (CF), highly resistant pathogens such as nontuberculous mycobacteria have emerged as an increasing challenge . Disease due to M. abscessus is of particular concern as it is associated with increased healthcare utilisation, accelerated lung function decline, impaired quality of life (QoL) , adverse impacts on post-lung transplant outcomes , and increased mortality . Good quality evidence to support current treatment regimens is lacking, and access to effective antimicrobial treatment options is limited.